
Contributions
Abstract: P250
Type: Poster Presentation
Presentation during EHA22: On Friday, June 23, 2017 from 17:15 - 18:45
Location: Poster area (Hall 7)
Background
Aims
The aim of this comprehensive nationwide population-based study was to assess trends in incidence, primary treatment and survival among HCL pts diagnosed in the Netherlands.
Methods
We selected all adult (≥18 years) pts diagnosed with classic HCL in the Netherlands between 1989-2014 from the nationwide Netherlands Cancer Registry with survival follow-up through February, 2016. Age-standardized incidence rates (ASR) were calculated per 1,000,000 person-years and standardized according to the European standard population. Data on primary treatment (i.e. no therapy, chemotherapy [CT] and immumotherapy [IT]) were available for individual pts. Pts were categorized into 2 periods (1989-2000 and 2001-2014) and 3 age groups (18-59, 60-69 and ≥70 years). We calculated relative survival (RS) and the relative excess risk of mortality as measures of disease-specific survival.
Results
Conclusion
The incidence of HCL remained stable during a 26-year period in the Netherlands. RS for pts diagnosed in the period 2001-2014 eventually reached a plateau, indicating that by then their survival is comparable to that of the general population. Survival was already excellent for younger patients throughout the entire study period. Survival improvement was most pronounced for pts age ≥60, although it was not statistically significant for pts age ≥70. This could be explained by the increased use CT over time. Population-based cancer registries are useful instruments to assess outcomes of pts rarely included in clinical trials.
Session topic: 6. Chronic lymphocytic leukemia and related disorders - Clinical
Keyword(s): epidemiology, Treatment, Survival, Hairy cell leukemia
Abstract: P250
Type: Poster Presentation
Presentation during EHA22: On Friday, June 23, 2017 from 17:15 - 18:45
Location: Poster area (Hall 7)
Background
Aims
The aim of this comprehensive nationwide population-based study was to assess trends in incidence, primary treatment and survival among HCL pts diagnosed in the Netherlands.
Methods
We selected all adult (≥18 years) pts diagnosed with classic HCL in the Netherlands between 1989-2014 from the nationwide Netherlands Cancer Registry with survival follow-up through February, 2016. Age-standardized incidence rates (ASR) were calculated per 1,000,000 person-years and standardized according to the European standard population. Data on primary treatment (i.e. no therapy, chemotherapy [CT] and immumotherapy [IT]) were available for individual pts. Pts were categorized into 2 periods (1989-2000 and 2001-2014) and 3 age groups (18-59, 60-69 and ≥70 years). We calculated relative survival (RS) and the relative excess risk of mortality as measures of disease-specific survival.
Results
Conclusion
The incidence of HCL remained stable during a 26-year period in the Netherlands. RS for pts diagnosed in the period 2001-2014 eventually reached a plateau, indicating that by then their survival is comparable to that of the general population. Survival was already excellent for younger patients throughout the entire study period. Survival improvement was most pronounced for pts age ≥60, although it was not statistically significant for pts age ≥70. This could be explained by the increased use CT over time. Population-based cancer registries are useful instruments to assess outcomes of pts rarely included in clinical trials.
Session topic: 6. Chronic lymphocytic leukemia and related disorders - Clinical
Keyword(s): epidemiology, Treatment, Survival, Hairy cell leukemia